Treatment programs in the National Drug Abuse Treatment Clinical Trials Network

Abstract

Drug abuse treatment programs and university-based research centers collaborate to test emerging therapies for alcohol and drug disorders in the National Drug Abuse Treatment Clinical Trials Network (CTN). Programs participating in the CTN completed organizational (n = 106 of 112; 95% response rate) and treatment unit surveys (n = 348 of 384; 91% response rate) to describe the levels of care, ancillary services, patient demographics, patient drug use and co-occurring conditions. Analyses describe the corporations participating in the CTN and provide an exploratory assessment of variation in treatment philosophies. A diversity of treatment centers participate in the CTN; not Conflict of Interest None of the authors report conflicts of interest.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Medicine, 1998, p. 123). After receiving public testimony and evaluating potential strategies, the Committee proposed that NIDA support a research/ practice infrastructure where investigators and treatment programs collaborate to facilitate adoption of evidence-based practices (Recommendation 1, p. 6). NIH Public Access National Drug Abuse Treatment Clinical Trials NetworkIn 1999, the National Institute on Drug Abuse issued awards to support the National Drug Abuse Treatment Clinical Trials Network (CTN). The CTN uses multi-site clinical trials to test behavioral, pharmacological, and integrated behavioral and pharmacological treatment interventions in a broad range of treatment programs with heterogeneous patient populations. Each node includes community treatment programs in partnership with a research center. In January of 2003, there were 17 nodes and 112 treatment providers. Treatment PhilosophyClinics addressing alcohol and drug disorders vary in treatment philosophies, and that variation may influence the adoption and use of specific treatment strategies. The Institute of Medicine identified three program philosophies or orientations that guide treatment strategies: physiological (addiction is a progressive disease that requires medical intervention including the use of pharmacotherapy), psychological (addiction is a behavioral and emotional problem that responds to intensive group and individual therapy), and sociocultural (addiction is the result of socialization in environments that promote use of alcohol and other drugs and treatment requires environmental restructuring and new social relationships) (Institute of Medicine 1990). These models of care are not mutually exclusive but reflect service priorities.Social model programs, for example, articulate six core beli...

Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network

“…Similarities in the CTN participant characteristics population provide a rationale for pooling across trial, such as socioeconomic status, racial and ethnic groups, employment status, and educational level (Calsyn et al, 2009; Campbell et al, 2010; Carroll et al, 2006; Donovan et al, 2013; Hien et al, 2010; Hien et al, 2009; Horigian, Robbins, Dominguez, Ucha, & Rosa, 2010; Korthuis et al, 2012; Kropp et al, 2013; Masson et al, 2013; Meade et al, 2010; Svikis et al, 2012; Weiss et al, 2011; Winhusen, Winstanley, Somoza, & Brigham, 2012; Woody et al, 2008). Participants were typically recruited from community-based substance abuse treatment programs (CTPs) within the CTN network (McCarty et al, 2008) and trials were designed by NIDA CTN investigators with common goals of bridging practice with substance abuse treatment research results (Tai et al, 2010; Wells, Saxon, Calsyn, Jackson, & Donovan, 2010b). In addition, there was no statistical evidence that mortality rates differed across these CTN trials.…”

Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities

“…The survey was designed by the Advisory Board drawing on examples of other surveys of substance abuse treatment programs, including the National Drug Abuse Treatment System Survey (Andrews et al, 2014), the Comprehensive Community Mental Health Services for Children and Their Families Program Evaluation (Center for Mental Health Services, 2005), the University of Georgia National Treatment Center Study (Knudsen et al, 2011b), and the Assessment of the National Drug Abuse Treatment Clinical Trials Network Suvey (McCarty et al, 2008) as well as the results of the qualitative interviews and focus groups conducted in the second phase of the project. The survey consisted of 17 sections: background information about the respondent and program, program workforce, assessment process, quality improvement and training procedures, and individual sections for the 12 EBTs described below.…”

Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network

“…The CTN is comprised of centers across the US that vary widely in terms of patient demographics, services provided, level of care, etc. [69]. Sites interested in participating in the ACCENT study initially completed surveys that described their previous performance in conducting research, potential participant pools, recruitment strategies, and any regulatory issues.…”